In recent years, chimeric antigen receptor T-cell (CAR-T) therapy has made breakthroughs in the treatment of hematological tumors. However, due to the different characteristics of solid tumors from hematological tumor...In recent years, chimeric antigen receptor T-cell (CAR-T) therapy has made breakthroughs in the treatment of hematological tumors. However, due to the different characteristics of solid tumors from hematological tumors, CAR-T has not achieved good efficacy in the treatment of solid tumors. The key factors limiting the efficacy of CAR-T mainly include the solid tumor cells themselves and their special tumor microenvironment (TME), which damage CAR-T function in multiple processes such as CAR-T infiltration to tumor tissue sites, CAR-T maintaining anti-tumor activity in TME, and target recognition and killing of tumor cells by CAR-T. To solve these problems, more and more preclinical studies have proposed potentially effective solutions, and corresponding clinical studies have been carried out one after another. In this article, the existing challenges and corresponding optimization strategies of CAR-T cell therapy for solid tumors will be reviewed, to provide a reference for the future exploration of CAR-T therapy.展开更多
At 04∶50 on January 1,2021,a 36-year-old Chinese project manager(Case A),a 29-year-old Chinese worker(Case B),and a 53-year-old Chinese businessman(Case C)returned from Africa(Case A and B from South Africa and Case ...At 04∶50 on January 1,2021,a 36-year-old Chinese project manager(Case A),a 29-year-old Chinese worker(Case B),and a 53-year-old Chinese businessman(Case C)returned from Africa(Case A and B from South Africa and Case C from Lesotho)on the same flight and tested coronavirus disease 2019(COVID-19)RNA positive by real-time polymerase chain reaction(PCR)by Baoan District People’s Hospital.Shenzhen CDC received their oral nasopharyngeal swabs packages from the hospital and retested COVID-19 RNA positive at 09∶50.Meanwhile,Case D.展开更多
文摘In recent years, chimeric antigen receptor T-cell (CAR-T) therapy has made breakthroughs in the treatment of hematological tumors. However, due to the different characteristics of solid tumors from hematological tumors, CAR-T has not achieved good efficacy in the treatment of solid tumors. The key factors limiting the efficacy of CAR-T mainly include the solid tumor cells themselves and their special tumor microenvironment (TME), which damage CAR-T function in multiple processes such as CAR-T infiltration to tumor tissue sites, CAR-T maintaining anti-tumor activity in TME, and target recognition and killing of tumor cells by CAR-T. To solve these problems, more and more preclinical studies have proposed potentially effective solutions, and corresponding clinical studies have been carried out one after another. In this article, the existing challenges and corresponding optimization strategies of CAR-T cell therapy for solid tumors will be reviewed, to provide a reference for the future exploration of CAR-T therapy.
基金Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences(NO.2020-PT330-006)Shenzhen Key Medical Discipline Construction Fund(NO.SZXK064)+1 种基金Sanming Project of Medicine in Shenzhen(NO.SZSM 201811071)the China National Science and Technology Major Projects Foundation(NO.2017ZX10303406).
文摘At 04∶50 on January 1,2021,a 36-year-old Chinese project manager(Case A),a 29-year-old Chinese worker(Case B),and a 53-year-old Chinese businessman(Case C)returned from Africa(Case A and B from South Africa and Case C from Lesotho)on the same flight and tested coronavirus disease 2019(COVID-19)RNA positive by real-time polymerase chain reaction(PCR)by Baoan District People’s Hospital.Shenzhen CDC received their oral nasopharyngeal swabs packages from the hospital and retested COVID-19 RNA positive at 09∶50.Meanwhile,Case D.
